항독소 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the antivenom market size is projected to be USD 1.24 billion in 2025, USD 1.28 billion in 2026, and reach USD 1.49 billion by 2031, growing at a CAGR of 3.13% from 2026 to 2031.

This report is Segmented by Product Type (Polyvalent, and More), Source (Equine-Derived, Ovine-Derived, and Recombinant DNA/Monoclonal), End-User (Hospitals, Clinics & Trauma Centres, and Military & Special-Purpose), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). Market Forecasts are Provided in Terms of Value (USD).

Global Antivenom Market Trends and Insights

Rising Incidence of Venomous Bites and Stings

WHO records show 5.4 million snakebites a year, resulting in up to 138,000 deaths and 400,000 life-long disabilities. India alone accounts for nearly half of global mortality, with peak cases during the monsoon planting season, when agricultural workers encounter kraits and cobras. Climate change is extending the range of venomous species into former temperate zones, enlarging the addressable patient pool. Under-reporting skews official counts downward; field studies indicate the real incidence could be 30-50% higher. Unless stockpiling and local production accelerate, demand may outpace the projected growth rate of the antivenom market, stressing current supply chains.

Expansion of Government Funding and Stockpiling Programs

Following WHO guidance, many high-burden countries now budget for proactive antivenom reserves rather than ad-hoc purchases. India mandates antivenom at primary health centers, guaranteeing offtake for domestic producers such as Serum Institute and Bharat Serums. Brazil's public system relies on Instituto Butantan for national supply, illustrating vertical integration that insulates against import shocks. Military agencies in the United States and NATO allies also procure antivenoms for troops, creating a non-cyclical demand floor. Combined civilian and defense orders stabilize revenue, enabling manufacturers to invest in capacity upgrades.

Inadequate Cold Chain & Distribution Logistics

Antivenoms must be kept between 2-8 °C from the factory to the bedside, yet rural clinics often lack reliable power for refrigeration. Temperature excursions during last-mile transport degrade potency, wasting scarce inventory. Solar-powered refrigerators and portable carriers exist, but space is limited, competing with vaccines and insulin, leading to triage decisions based on turnover rather than clinical need. Ad hoc courier networks rarely monitor temperature, leaving health posts unaware of spoilage risks. Thermostable or lyophilized formulations could unlock untapped rural demand, but these technologies are still in early deployment.

Other drivers and restraints analyzed in the detailed report include:

1. Advancements in Recombinant & Monoclonal Technologies
2. International Regulatory Harmonization and WHO Prequalification
3. Venom Diversity Limiting Cross-Neutralization Efficacy

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Polyvalent antivenoms captured 62.43% of the antivenom market share in 2025, as emergency departments prefer broad-spectrum coverage to simplify inventory management. Other product formats such as lyophilized powders, Fab fragments, and experimental recombinant constructs are projected to expand at a 5.65% CAGR, signaling rising interest in precision therapy.

Hospitals value the one-vial-fits-many convenience of polyvalent products, yet these products carry antibodies irrelevant to each case, heightening the risk of adverse reactions. Regulatory guidance released in 2025 favors next-generation formats that meet tighter purity and stability metrics. Lyophilized versions remove cold-chain constraints, appealing to military and remote clinics, although reconstitution adds a time-critical step. As clinical evidence mounts, polyvalent dominance will erode gradually, making early investment in thermostable or recombinant lines a strategic play for 2030 and beyond.

Complete Report Scope:

• By Product Type
  • Polyvalent
  • Monovalent
  • Other Product Types
• By Source
  • Equine-Derived
  • Ovine-Derived
  • Recombinant (DNA/Monoclonal)
• By End-User
  • Hospitals
  • Clinics & Trauma Centres
  • Military & Special-Purpose
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 43.54% of the antivenom market revenue in 2025, supported by established hospital contracts and Defense Department procurement. Supply fragility persists; FDA extended Pfizer's coral snake antivenin shelf life in 2025 because no alternative was available. Willingness to pay is high, enabling premium products like small-molecule varespladib-methyl to progress under Fast Track status.

Asia-Pacific is projected to register the fastest regional CAGR at 4.54% through 2031. India records 46,000 snakebite deaths annually, prompting domestic firms such as the Serum Institute and Bharat Serums to scale up production. Rural trauma infrastructure and 11 home-grown mobile snakebite apps improve patient routing. China's Healthy China 2030 blueprint places antivenom on essential lists for township clinics, although detailed volumes remain undisclosed.

Europe, Middle East & Africa, and South America occupy the balance of demand. Sub-Saharan Africa now uses WHO's eSURV platform in 46 countries, recording over 554,000 facility visits for snakebite since 2024. Public-private models, such as CSL's Papua New Guinea donations, show how targeted programs can reach orphan geographies. Market expansion in these regions hinges on replacing substandard imports with WHO-approved options and securing donor finance.

1. Bharat Serums & Vaccines Ltd.
2. BTG plc (Protherics UK Ltd.)
3. CSL Behring
4. Haffkine Bio-Pharmaceutical Corp.
5. Incepta Pharmaceuticals Ltd.
6. Instituto Butantan
7. Instituto Clodomiro Picado
8. Instituto Vital Brazil
9. Merck
10. Kamada Ltd.
11. Laboratorios Bioclon S.A. de C.V.
12. MicroPharm Ltd.
13. Ophirex Inc.
14. Pfizer
15. Rare Disease Therapeutics
16. Sanofi (Sanofi Pasteur)
17. Serum Institute Of India
18. South African Vaccine Producers (Pty) Ltd.
19. Venomtech Ltd.
20. Vins Bioproducts Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Incidence of Venomous Bites and Stings
  • 4.2.2 Expansion of Government Funding and Stockpiling Programs
  • 4.2.3 Advancements in Recombinant and Monoclonal Antivenom Technologies
  • 4.2.4 Strengthening Rural Healthcare and Emergency Infrastructure
  • 4.2.5 International Regulatory Harmonization and WHO Pre-Qualification
  • 4.2.6 Growing Public Awareness and Digital Reporting Platforms
• 4.3 Market Restraints
  • 4.3.1 Inadequate Cold Chain and Distribution Logistics
  • 4.3.2 Venom Diversity Limiting Cross-Neutralization Efficacy
  • 4.3.3 Adverse Immunogenic Reactions to Animal-Derived Antivenoms
  • 4.3.4 Fluctuating Supply of High-Quality Equine/Ovine Plasma
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Polyvalent
  • 5.1.2 Monovalent
  • 5.1.3 Other Product Types
• 5.2 By Source
  • 5.2.1 Equine-Derived
  • 5.2.2 Ovine-Derived
  • 5.2.3 Recombinant (DNA/Monoclonal)
• 5.3 By End-User
  • 5.3.1 Hospitals
  • 5.3.2 Clinics & Trauma Centres
  • 5.3.3 Military & Special-Purpose
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(Includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products & Services, And Recent Developments)}
  • 6.3.1 Bharat Serums & Vaccines Ltd.
  • 6.3.2 BTG plc (Protherics UK Ltd.)
  • 6.3.3 CSL Limited
  • 6.3.4 Haffkine Bio-Pharmaceutical Corp.
  • 6.3.5 Incepta Pharmaceuticals Ltd.
  • 6.3.6 Instituto Butantan
  • 6.3.7 Instituto Clodomiro Picado
  • 6.3.8 Instituto Vital Brazil
  • 6.3.9 Merck & Co., Inc.
  • 6.3.10 Kamada Ltd.
  • 6.3.11 Laboratorios Bioclon S.A. de C.V.
  • 6.3.12 MicroPharm Ltd.
  • 6.3.13 Ophirex Inc.
  • 6.3.14 Pfizer Inc.
  • 6.3.15 Rare Disease Therapeutics Inc.
  • 6.3.16 Sanofi (Sanofi Pasteur)
  • 6.3.17 Serum Institute Of India
  • 6.3.18 South African Vaccine Producers (Pty) Ltd.
  • 6.3.19 Venomtech Ltd.
  • 6.3.20 Vins Bioproducts Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment